Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus.

Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Apr 2008Cited by 54 (Europe PMC)

PMID18463034DOI10.4158/ep.14.3.285PepBankPUB-18463034

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studySafety outcome
In insulin-treated patients with type 2 diabetes, 48 patients discontinued exenatide during the first year, primarily because of gastrointestinal intolerance.
In plain wordsIn insulin-treated people with diabetes, exenatide discontinuation occurred mainly because of digestive intolerance.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableExenatide discontinuation
Study
n = 134
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Discontinuations
48 patients
first year
Discontinuation rate
36%
first year
Source sentences
Summary
Forty-eight patients (36%) discontinued exenatide therapy during the first year, primarily attributable to gastrointestinal intolerance.
1 context sentence(design, population, supporting numbers)
Summary · context
Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy.
Report a problemFND-1846303408
02HumanObservational studySafety outcome
In insulin-treated patients with type 2 diabetes, 14 patients experienced hypoglycemia during exenatide treatment, mostly mild.
In plain wordsIn insulin-treated people with diabetes, hypoglycemia during exenatide treatment was mostly mild.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHypoglycemia
Study
n = 134
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Hypoglycemia
14 patients
exenatide with insulin
Hypoglycemia rate
10%
exenatide with insulin
Source sentences
Summary
Fourteen patients (10%) experienced hypoglycemia, most of which was mild.
1 context sentence(design, population, supporting numbers)
Summary · context
Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy.
Report a problemFND-1846303410
03HumanObservational studyEfficacy outcome
In insulin-treated patients with type 2 diabetes, exenatide initiation was associated with an A1C reduction from baseline.
In plain wordsIn insulin-treated people with diabetes, starting exenatide was linked to lower A1C than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
A1C reduction
0.87%
exenatide added to insulin
Source sentences
Summary
Exenatide use resulted in a significant 0.87% reduction in A1C (P<.001),
1 context sentence(design, population, supporting numbers)
Summary · context
Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy.
Report a problemFND-1846303401
04HumanObservational studyEfficacy outcome
In insulin-treated patients with type 2 diabetes, exenatide initiation was associated with 45% discontinuation of premeal insulin use.
In plain wordsIn insulin-treated people with diabetes, starting exenatide was linked to 45% stopping premeal insulin.
Peptide
Exenatide (exendin-4)
Outcome
Not applicablePremeal insulin discontinuation
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Premeal insulin discontinuation
45%
exenatide initiation
Source sentences
Summary
despite a 45% discontinuation of premeal insulin use (P<.001),
1 context sentence(design, population, supporting numbers)
Summary · context
Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy.
Report a problemFND-1846303402
05HumanObservational studyEfficacy outcome
In insulin-treated patients with type 2 diabetes, exenatide initiation was associated with a 9-U reduction in mean premeal insulin dose.
In plain wordsIn insulin-treated people with diabetes, starting exenatide was linked to lower premeal insulin doses than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMean premeal insulin dose
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Mean premeal insulin dose reduction
9 U
exenatide initiation
Source sentences
Summary
a 9-U reduction in mean premeal insulin doses (P = .0066),
1 context sentence(design, population, supporting numbers)
Summary · context
Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy.
Report a problemFND-1846303403
06HumanObservational studyEfficacy outcome
In insulin-treated patients with type 2 diabetes, exenatide initiation was associated with fewer daily insulin injections than baseline.
In plain wordsIn insulin-treated people with diabetes, starting exenatide was linked to fewer daily insulin injections than baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDaily insulin injections
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Median daily insulin injections
2 injections/day
baseline
Median daily insulin injections
1 injections/day
follow-up
Source sentences
Summary
a reduction in the median number of daily insulin injections from 2 to 1 (P = .0053),
1 context sentence(design, population, supporting numbers)
Summary · context
Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy.
Report a problemFND-1846303404
07HumanObservational studyEfficacy outcome
In insulin-treated patients with type 2 diabetes, exenatide initiation was associated with a 59% sulfonylurea discontinuation rate.
In plain wordsIn insulin-treated people with diabetes, starting exenatide was linked to 59% stopping sulfonylureas.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableSulfonylurea discontinuation
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Sulfonylurea discontinuation
59%
exenatide initiation
Source sentences
Summary
and a 59% discontinuation rate of sulfonylurea use (P = .0088).
1 context sentence(design, population, supporting numbers)
Summary · context
Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy.
Report a problemFND-1846303405
08HumanObservational studyEfficacy outcome
In insulin-treated patients with type 2 diabetes, exenatide initiation was associated with mean weight loss of 5.2 kg.
In plain wordsIn insulin-treated people with diabetes, starting exenatide was linked to weight loss compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMean weight change
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Mean weight loss
5.2 kg
exenatide initiation
Source sentences
Summary
Exenatide use was associated with a mean weight loss of 5.2 kg (P<.001), with 72% of evaluable patients losing weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy.
Report a problemFND-1846303406
09HumanObservational studyEfficacy outcome
In insulin-treated patients with type 2 diabetes, 72% of evaluable exenatide-treated patients lost weight.
In plain wordsIn insulin-treated people with diabetes, most evaluable exenatide-treated patients lost weight.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableAny weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Patients losing weight
72%
evaluable patients
Source sentences
Summary
Exenatide use was associated with a mean weight loss of 5.2 kg (P<.001), with 72% of evaluable patients losing weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy.
Report a problemFND-1846303407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.